<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9971">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05686356</url>
  </required_header>
  <id_info>
    <org_study_id>AUR1-1-312</org_study_id>
    <secondary_id>24206</secondary_id>
    <secondary_id>6986</secondary_id>
    <secondary_id>RIA2019AMR-2647</secondary_id>
    <nct_id>NCT05686356</nct_id>
  </id_info>
  <brief_title>A Pan-TB Regimen Targeting Host and Microbe</brief_title>
  <acronym>panTB-HM</acronym>
  <official_title>A Novel 4-month Pan-TB Regimen Targeting Both Host and Microbe (panTB-HM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Aurum Institute NPC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stichting Katholieke Universiteit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wits Health Consortium (Pty) Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto Nacional de Sa√∫de, Mozambique</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute for Medical Research, Tanzania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Stellenbosch</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sequella, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Global Alliance for TB Drug Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Aurum Institute NPC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project will develop the first regimen meeting WHO criteria for a pan-TB indication, ie,&#xD;
      not requiring knowledge of RIF susceptibility. The regimen will test sutezolid at 2 dose&#xD;
      levels, with the approved anti-TB drugs bedaquiline and pretomanid, in a phase 2c trial. It&#xD;
      will also test whether the addition of N-acetylcysteine (NAC), a re-purposed host-directed&#xD;
      WHO essential medicine, can protect the lung and liver against oxidative damage, preserve&#xD;
      lung function, and accelerate the eradication of MTB infection by replenishing glutathione&#xD;
      (GSH).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2023</start_date>
  <completion_date type="Anticipated">September 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2025</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients achieving durable (non-relapsing) cure</measure>
    <time_frame>Assessed after 1 year of post-treatment follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with TE ALT increases, graded according to severity</measure>
    <time_frame>From day 1 through 4 weeks post end-of-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with TE increases in transaminases and bilirubin meeting Hy's criteria for serious liver injury</measure>
    <time_frame>From day 1 through 4 weeks post end-of-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with TE AEs, according to seriousness</measure>
    <time_frame>From day 1 through 4 weeks post end-of-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of TE AEs per treatment arm, according to seriousness</measure>
    <time_frame>From day 1 through 4 weeks post end-of-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects requiring temporary or permanent treatment discontinuation due to safety or tolerability concerns</measure>
    <time_frame>From day 1 through 4 weeks post end-of-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 and FVC at 1, 2, 6, and 18 months after initiation of treatment</measure>
    <time_frame>1, 2, 6, and 18 months after initiation of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 and FVC slope during 6 and 18 months after initiation of treatment</measure>
    <time_frame>6 and 18 months after initiation of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1/FVC ratio at 1, 2, 6, and 18 months after initiation of treatment</measure>
    <time_frame>1, 2, 6, and 18 months after initiation of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with sputum cultures showing growth of MTB at 1, 2, 3, and 4 months after initiation of treatment</measure>
    <time_frame>1, 2, 3, and 4 months after initiation of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The hazard ratio for stable culture conversion through the 4th month of treatment</measure>
    <time_frame>through the 4th month of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with treatment failure</measure>
    <time_frame>More than 1 specimen showing growth of MTB during the final 6 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with relapse</measure>
    <time_frame>At week 72 for the control arm and at week 64 for the experimental arms</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>The proportion of subjects with non-TB cardiac or pulmonary AEs during the 18 months after TB diagnosis, according to seriousness.</measure>
    <time_frame>During the 18 months after TB diagnosis</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The plasma concentration (AUC) of sutezolid and its main metabolite</measure>
    <time_frame>Month 1</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The plasma concentration (Cmax and Cmin) of sutezolid and its main metabolite</measure>
    <time_frame>Month 1</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The plasma concentration (T&gt;MIC) of sutezolid and its main metabolite</measure>
    <time_frame>Month 1</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">352</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Arm 1 (S1200BP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sutezolid 1200mg QD plus bedaquiline and pretomanid for 4 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 (S1600BP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sutezolid 1600mg QD plus bedaquiline and pretomanid for 4 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3 (S1600BPN)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sutezolid 1600mg QD plus bedaquiline pretomanid and N-acetyl cysteine for 4 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4 (HRZE)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rifafour (2HRZE/4HR)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sutezolid</intervention_name>
    <description>Sutezolid will be given at a dose of 1200mg QD in arm 1 and at a dose of 1600mg QD in arms 2 and 3.</description>
    <arm_group_label>Arm 1 (S1200BP)</arm_group_label>
    <arm_group_label>Arm 2 (S1600BP)</arm_group_label>
    <arm_group_label>Arm 3 (S1600BPN)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetyl cysteine</intervention_name>
    <description>NAC will be given at a dose of 1800 mg BID in arm 3</description>
    <arm_group_label>Arm 3 (S1600BPN)</arm_group_label>
    <other_name>NAC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pretomanid</intervention_name>
    <description>Pretomanid will be given at its approved dose</description>
    <arm_group_label>Arm 1 (S1200BP)</arm_group_label>
    <arm_group_label>Arm 2 (S1600BP)</arm_group_label>
    <arm_group_label>Arm 3 (S1600BPN)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bedaquiline</intervention_name>
    <description>Bedaquiline will be given at its approved dose</description>
    <arm_group_label>Arm 1 (S1200BP)</arm_group_label>
    <arm_group_label>Arm 2 (S1600BP)</arm_group_label>
    <arm_group_label>Arm 3 (S1600BPN)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Rifafour</intervention_name>
    <description>Fixed dose combination tablets for TB treatment will be given at approved doses</description>
    <arm_group_label>Arm 4 (HRZE)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 18 to 65 years&#xD;
&#xD;
          2. Willing and able to provide signed written consent prior to undertaking any&#xD;
             trial-related procedures, or, in the case of illiteracy, witnessed oral consent&#xD;
&#xD;
          3. Body weight (in light clothing without shoes) between 30 and 90 kg.&#xD;
&#xD;
          4. Radiographic evidence of pulmonary tuberculosis&#xD;
&#xD;
          5. Positive Xpert TB/RIF (original or Ultra) for MTB&#xD;
&#xD;
          6. RIF susceptibility diagnosed by Xpert TB/RIF, with subsequent culture confirmation&#xD;
&#xD;
          7. If sexually active, willing to use an effective contraceptive method for the duration&#xD;
             of tuberculosis treatment&#xD;
&#xD;
          8. HIV-1 seronegative, or if HIV-1 seropositive, CD4 T cell count ‚â•100/¬µl and either&#xD;
             receiving ART or willing to start ART during study participation&#xD;
&#xD;
          9. SARS-CoV-2 PCR or antigen test negative, or if positive, either fully vaccinated&#xD;
             against Covid-19 or with D-dimer &lt;0.8 ug/ml&#xD;
&#xD;
         10. Willing to adhere to a diet excluding tyramine-rich foods (certain mold-ripened&#xD;
             cheeses and cured meats), and to avoid eating grapefruits and pomelos&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any condition for which participation in the trial, as judged by the investigator,&#xD;
             could compromise the well-being of the subject or prevent, limit or confound protocol&#xD;
             specified assessments&#xD;
&#xD;
          2. Current or imminent (within 24 hr) treatment for malaria.&#xD;
&#xD;
          3. Pregnant or nursing&#xD;
&#xD;
          4. Is critically ill, and in the judgment of the investigator has a diagnosis likely to&#xD;
             result in death during the trial or the follow-up period.&#xD;
&#xD;
          5. TB meningitis or spondylitis, or other forms of severe tuberculosis with high risk of&#xD;
             a poor outcome as judged by the investigator.&#xD;
&#xD;
          6. History of allergy or hypersensitivity to any of the trial therapies or related&#xD;
             substances.&#xD;
&#xD;
          7. Having participated in other clinical trials with investigational agents within 8&#xD;
             weeks prior to trial start or currently enrolled in an investigational trial.&#xD;
&#xD;
          8. Prior TB treatment in the preceding 6 months&#xD;
&#xD;
          9. Angina pectoris requiring treatment with nitroglycerin or other nitrates&#xD;
&#xD;
         10. Cardiac arrhythmia requiring medication, or any clinically significant ECG&#xD;
             abnormality, in the opinion of the investigator&#xD;
&#xD;
         11. History of unstable Diabetes Mellitus requiring hospitalization for hyper- or&#xD;
             hypo-glycaemia within the past year prior to start of screening.&#xD;
&#xD;
         12. Use of systemic corticosteroids within the past 28 days.&#xD;
&#xD;
         13. Patients requiring treatment with medications not compatible with rifampin, such as&#xD;
             HIV-1 protease inhibitors&#xD;
&#xD;
         14. Patients requiring treatment with antidepressants, including MAO inhibitors and SSRIs.&#xD;
&#xD;
         15. Subjects with any of the following abnormal laboratory values:&#xD;
&#xD;
               1. HBsAg positive&#xD;
&#xD;
               2. creatinine &gt;2 mg/dL&#xD;
&#xD;
               3. hemoglobin &lt;8 g/dL&#xD;
&#xD;
               4. platelets &lt;100x109 cells/L&#xD;
&#xD;
               5. serum potassium &lt;3.5 mM/L&#xD;
&#xD;
               6. alanine aminotransferase (ALT) ‚â•2.0 x ULN&#xD;
&#xD;
               7. alkaline phosphatase (AP) &gt;5.0 x ULN&#xD;
&#xD;
               8. total bilirubin &gt;1.5 mg/dL&#xD;
&#xD;
               9. random blood glucose &gt;200 mg/dL&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Professor Robert Wallis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Aurum Institute NPC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Professor Robert Wallis</last_name>
    <phone>+1 (860) 271-6745</phone>
    <email>rwallis@auruminstitute.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mr Don L Mudzengi</last_name>
    <phone>+27833697946</phone>
    <email>dmudzengi@auruminstitute.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto Nacional de Sa√∫de</name>
      <address>
        <city>Maputo</city>
        <country>Mozambique</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr Celso Khosa, MD</last_name>
      <email>celso.khosa@ins.gov.mz</email>
    </contact>
    <contact_backup>
      <last_name>Dr Emilia Fumane, MD</last_name>
      <email>emilia.fumane@ins.gov.mz</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Clinical HIV Research Unit</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2092</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <contact>
      <last_name>Mohammed Rassool, Medical</last_name>
      <phone>+2711 276 8800</phone>
      <email>mrassool@witshealth.co.za</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Aurum Institute: Tembisa Clinical Research Centre</name>
      <address>
        <city>Tembisa</city>
        <state>Gauteng</state>
        <zip>1632</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr Modulakgotla Sebe, MBChB</last_name>
      <phone>27-87-1351645</phone>
      <email>msebe@auruminstitute.org</email>
    </contact>
    <contact_backup>
      <last_name>Don Mudzengi, MSc</last_name>
      <phone>+27 83 369 7946</phone>
      <email>dmudzengi@auruminstitute.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>NIMR-Mbeya Medical Research Centre</name>
      <address>
        <city>Mbeya</city>
        <country>Tanzania</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr Nyanda Ntinginya, MD, Phd</last_name>
      <phone>+255 25 2503364</phone>
      <email>nelias@nimr-mmrc.org</email>
    </contact>
    <contact_backup>
      <last_name>Dr Issa Sabi, MD, PhD</last_name>
      <email>emilia.fumane@ins.gov.mz</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Mozambique</country>
    <country>South Africa</country>
    <country>Tanzania</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>December 18, 2022</study_first_submitted>
  <study_first_submitted_qc>January 13, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2023</study_first_posted>
  <last_update_submitted>January 13, 2023</last_update_submitted>
  <last_update_submitted_qc>January 13, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>Bedaquiline</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

